Clinical trial · Observational
Role of CXCR2 Ligands/CXCR2 Biological Axis in Pancreatic Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators hypothesize that the CXCR2 ligands/CXCR2 biological axis plays an important role in promoting angiogenesis in PC; and that the genetic changes and the microenvironment of the tumor regulate the expression of CXCR2 ligands/CXCR2 in PC in order to potentiate their angiogenic phenotype. A corollary of this hypothesis is that the cell surface receptors (CXCR2) and the intracellular signaling pathways that mediate the angiogenic responses induced by ELR+ CXC-chemokines are potential targets for novel therapeutic interventions in PC.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Pancreatitis | — | UNRESOLVED | — |
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (3)
- label
- 1. Normal pancreas patients
- description
- Patients with no documented clinical history of pancreatic diseases supported by at least 1 negative imaging test (EUS, CT scan or MRI).
- label
- 2. Chronic pancreatitis patients
- description
- Patients with documented diagnosis of moderate to advanced chronic pancreatitis supported by at least 1 positive imaging test (EUS,CT scan or MRI).
- label
- 3. Pancreatic cancer patients
- description
- Patients with documented tissue diagnosis (or clinical suspicion) of Pancreatic Cancer.
Primary outcomes (1)
- measure
- All cause mortality
- timeFrame
- One year
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Normal subjects - No documented clinical history of pancreatic diseases supported by at least 1 negative imaging test. (EUS, Ct scan or MRI) * Chronic pancreatitis - Documented diagnosis of moderate to advanced chronic supported bpancreatitisy at least 1 positive imaging test. (EUS, Ct scan or MRI) * Pancreatic Cancer - Documented tissue diagnosis (or clinical suspicion) of Pancreatic Cancer. Exclusion Criteria: * Exclusion criteria will include age younger than 18 yrs, pregnancy, previous pancreatic or gastric resection, and inability to tolerate routine endoscopy with conscious sedation
References
Publications (0)
Data not yet available